Ascentage Pharma Group (AAPG) Q2 2024 Earnings Report

Ascentage Pharma reported QQ2 2024 revenue of CNY 823.75 million with a very high gross margin of 98.17%, underscoring the favorable revenue mix and product structure. Net income reached CNY 163.00 million, with EBITDA of CNY 229.59 million and an operating margin of 22.82%, signaling solid core profitability amidst a heavy R&D investment phase. R&D outlay totaled CNY 444.08 million (about 54% of revenue), reflecting the company’s continued emphasis on its multi-program oncology and HBV pipeline. Despite positive profitability, operating cash flow was negative at CNY -354.39 million and free cash flow negative at CNY -370.92 million, driven by substantial non-cash charges and working capital dynamics, alongside a material negative retained earnings balance over time. The balance sheet shows a robust cash position (CNY 1.10 billion) and an elevated leverage profile (net debt ~CNY 0.60 billion; debt-to-equity ≈ 2.22), implying funded R&D and pipeline investment but requiring vigilance on cash generation and liquidity as development milestones unfold. No earnings-call transcript data were provided in the materials; consequently, management quotes from the call could not be incorporated. Investors should monitor pipeline progress (HQP1351, APG2575, APG115, APG1387, APG2449, and related assets), potential partnerships, and regulatory milestones that could materially alter the risk-reward profile going forward.